HEALTHSTORY 1278· JUNE 20, 2026

Daraxonrasib Doubles Average Survival in Pancreatic Cancer, UCLA-Led Trial Shows

A UCLA-co-led international study presented May 31 at the American Society of Clinical Oncology annual meeting in Chicago reported that pancreatic cancer patients treated with daraxonrasib survived an average of 13.2 months — nearly double…

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 1277Nuclear Bros: Silicon Valley's Young Founders Race to Restart American Atomic Power NEXT STORY 1279 →U.S. Confirms Second Strike on Iran Targeting Air Defenses as Oil Prices Surge

Keep reading

More from the desk.

02HEALTH

Radiopharma giants merge in $1.65 billion deal after FDA rejection

Two leading radiopharmaceutical companies are merging in a transaction valued at at least $1.65 billion. This move follows a surprise FDA rejection for one of the firms. In plain terms, radiopharmaceuticals are medicines that deliver…

health2 MIN

25HEALTH

Sanfilippo syndrome gets its first gene therapy approval after more than a decade of research

A rare childhood disease called Sanfilippo syndrome now has an approved gene therapy, the first one in the disease's history. Gene therapy, in plain terms, is a treatment that introduces corrected genetic material into a patient's cells to…

health1 MIN

37HEALTH

A rare genetic variant raises lung cancer risk 25-fold in people who have never smoked

Researchers have identified a rare genetic variant tied to a 25-fold increase in lung cancer odds among people who have never smoked, according to a study published Thursday in the journal Science. A genetic variant is a small, inherited…

health2 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk